Form 4: Immuneering Corp Director Peter Feinberg Reports Stock Option Grant

Peter Feinberg, a director of Immuneering Corp, reported the acquisition of stock options on June 12, 2024.

Summary

• Peter Feinberg, a director of Immuneering Corp, filed a Form 4 to report changes in beneficial ownership.
• The report indicates that on June 12, 2024, Feinberg acquired stock options for 33,350 shares of Class A Common Stock.
• The exercise price of the stock options is $1.54.
• The options vest in equal monthly installments over one year, starting July 12, 2024, and will be fully vested by June 12, 2025, or the date of the 2025 annual meeting of stockholders, whichever comes first.
• Following the transaction, Feinberg directly owns derivative securities for 33,350 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, which is neither particularly positive nor negative. It reflects routine corporate governance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards increasing shareholder value.

Key Dates